Pfizer: cancer treatment attains significant improvement
(CercleFinance.com) - Pfizer and Japan's Astellas said on Tuesday that their drug to treat a form of prostate cancer significantly improves overall survival in patients tested in a late-stage study.
The results demonstrated a statistically significant improvement in overall survival in men with non-metastatic castration-resistant prostate cancer (nmCRPC) who were treated with Xtandi plus androgen deprivation therapy (ADT), the drugmakers said.
The detailed results of the final analysis will be shared at a later date, they said.
In 2018, Pfizer and Astellas said that the trial met its primary endpoint of metastasis-free survival.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The results demonstrated a statistically significant improvement in overall survival in men with non-metastatic castration-resistant prostate cancer (nmCRPC) who were treated with Xtandi plus androgen deprivation therapy (ADT), the drugmakers said.
The detailed results of the final analysis will be shared at a later date, they said.
In 2018, Pfizer and Astellas said that the trial met its primary endpoint of metastasis-free survival.
Copyright (c) 2020 CercleFinance.com. All rights reserved.